{"protocolSection": {"identificationModule": {"nctId": "NCT03557307", "orgStudyIdInfo": {"id": "D3250C00065"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma", "officialTitle": "PONENTE: A Multicenter, Open-label, Phase 3b Efficacy and Safety Study of Benralizumab 30 mg Administered Subcutaneously to Reduce Oral Corticosteroid Use in Adult Patients With Severe Eosinophilic Asthma on High Dose Inhaled Corticosteroid Plus Long-acting \u03b22 Agonist and Chronic Oral Corticosteroid Therapy", "acronym": "PONENTE"}, "statusModule": {"statusVerifiedDate": "2023-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2018-08-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2021-04-16", "type": "ACTUAL"}, "completionDateStruct": {"date": "2022-03-24", "type": "ACTUAL"}, "studyFirstSubmitDate": "2018-05-14", "studyFirstSubmitQcDate": "2018-06-04", "studyFirstPostDateStruct": {"date": "2018-06-15", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2022-02-07", "resultsFirstSubmitQcDate": "2022-06-22", "resultsFirstPostDateStruct": {"date": "2022-06-28", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-05-09", "lastUpdatePostDateStruct": {"date": "2023-06-06", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false, "isUsExport": true}, "descriptionModule": {"briefSummary": "This is a study designed to evaluate efficacy and safety of Benralizumab in reducing the Oral Corticosteroid (OCS) use in adult patients with severe asthma who are receiving OCS with or without additional asthma controller medications.", "detailedDescription": "This is an open-label, multicenter study designed to evaluate efficacy and safety of reducing daily oral corticosteroid (OCS) use after initiation of 30 mg dose of benralizumab administered subcutaneously (SC) in patients with severe eosinophilic asthma receiving high-dose inhaled corticosteroid (ICS)/long-acting \u03b22 agonist (LABA) and OCS with or without additional asthma controller(s)."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma", "Severe Asthma", "Oral Corticosteroids"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "SINGLE_GROUP", "interventionModelDescription": "Open label", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 598, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Benralizumab", "type": "EXPERIMENTAL", "description": "Benralizumab subcutaneous injection", "interventionNames": ["Biological: Benralizumab"]}], "interventions": [{"type": "BIOLOGICAL", "name": "Benralizumab", "description": "Benralizumab subcutaneous injection", "armGroupLabels": ["Benralizumab"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Patients Who Achieve 100% Reduction in Daily OCS Dose", "description": "Patients who achieve 100% reduction in daily OCS dose that are sustained over at least 4 weeks without worsening of asthma", "timeFrame": "Baseline to end of OCS reduction phase, an average of approximately 200 days (The duration of the OCS reduction phase may vary based on asthma exacerbations, asthma worsening, HPA integrity , or other safety issues altering the OCS titration schedule.)"}, {"measure": "Patients Who Achieve 100% Reduction or a Daily OCS Dose of <=5mg", "description": "Patients who achieve 100% reduction or a daily OCS dose of \\<=5mg, if reason for no further OCS reduction is Adrenal Insufficiency, that are sustained over at least 4 weeks without worsening of asthma", "timeFrame": "Baseline to end of OCS reduction phase, an average of approximately 200 days (The duration of the OCS reduction phase may vary based on asthma exacerbations, asthma worsening, HPA integrity , or other safety issues altering the OCS titration schedule.)"}], "secondaryOutcomes": [{"measure": "Patients Who Achieve a Daily OCS of \u22645mg", "description": "Patients who achieve a daily OCS dose of \u22645 mg (regardless of reason for no further OCS reduction), that are sustained over at least 4 weeks without worsening of asthma", "timeFrame": "Baseline to end of OCS reduction phase, an average of approximately 200 days (The duration of the OCS reduction phase may vary based on asthma exacerbations, asthma worsening, HPA integrity , or other safety issues altering the OCS titration schedule.)"}, {"measure": "Patients Who Achieve a \u226590%, \u226575%, and \u226550% Reduction in Daily OCS Dose", "description": "Patients who achieve a \u226590%, \u226575%, and \u226550% reduction in daily OCS dose that are sustained over at least 4 weeks without worsening of asthma", "timeFrame": "Baseline to end of OCS reduction phase, an average of approximately 200 days (The duration of the OCS reduction phase may vary based on asthma exacerbations, asthma worsening, HPA integrity , or other safety issues altering the OCS titration schedule.)"}, {"measure": "Change From Baseline in Average Daily OCS Dose (mg)", "description": "Change from baseline in average daily OCS dose (mg) from start of OCS reduction to end of the OCS reduction phase", "timeFrame": "Baseline to end of OCS reduction phase, an average of approximately 200 days (The duration of the OCS reduction phase may vary based on asthma exacerbations, asthma worsening, HPA integrity , or other safety issues altering the OCS titration schedule.)"}], "otherOutcomes": [{"measure": "Patients Who Achieve 100% Reduction in Daily OCS Dose From Main Study Baseline OCS Dose to the End of the Long Term Follow up Substudy", "description": "Patients who achieve 100% reduction in daily OCS dose that are sustained over at least 4 weeks without worsening of asthma", "timeFrame": "from main study baseline to the end of the long term follow up substudy, an average of approximate 922 days."}, {"measure": "Patients Who Achieve a Daily OCS Dose of \u22645 mg at the End of the Long Term Follow up Substudy", "description": "Patients who achieve a daily OCS dose of \u22645 mg (regardless of reason for no further OCS reduction), that are sustained over at least 4 weeks without worsening of asthma", "timeFrame": "from main study baseline to the end of the long term follow up substudy, an average of approximate 922 days."}, {"measure": "Patients Who Achieve \u226590%, \u226575%, \u226550% or >0% OCS Reduction From Main Study Baseline OCS Dose to the End of the Long Term Follow up Substudy", "description": "Patients who achieve a \u226590%, \u226575%, and \u226550% reduction in daily OCS dose that are sustained over at least 4 weeks without worsening of asthma", "timeFrame": "from main study baseline to the end of the long term follow up substudy, an average of approximate 922 days."}, {"measure": "Change in Daily OCS Dose (mg) From Main Study Baseline to the End of the Long Term Follow up Substudy", "description": "Change in average daily OCS dose (mg) from main study baseline to the end of the long term follow up substudy", "timeFrame": "from main study baseline to the end of the long term follow up substudy, an average of approximate 922 days."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Peripheral blood eosinophil count of \u2265150 cells/\u03bcL assessed by central lab at Visit 1 or \u2265 300 cells/\u03bcL in the past 12 months\n2. History of physician diagnosed asthma requiring continuous treatment with high dose ICS (high-dose ICS is budesonide/formoterol HFA \u2265640/18 per day or equivalent, fluticasone propionate DPI \\> 500/day or equivalent, or authorized generics for these products) plus LABA for at least 6 months prior to Visit 1. The ICS and LABA can be contained within a combination product or given by separate inhalers. The ICS can also be given via nebulized solution for inhalation.\n3. Chronic oral corticosteroid therapy equivalent to a daily dose of at least 5 mg of prednisone, for at least 3 continuous months directly preceding Visit 1.\n4. Patient should be on a stable OCS dose for at least 4 weeks prior to Visit 1.\n5. Non-smokers, current smokers or former smokers with a smoking history of \\< or =20 pack-years at Visit 1\n\nExclusion Criteria:\n\n1. Clinically important pulmonary disease other than asthma or ever been diagnosed with pulmonary or systemic disease, other than asthma, that are associated with elevated peripheral eosinophil counts\n2. Known history of allergy or reaction to the study drug formulation\n3. History of anaphylaxis to any biologic therapy\n4. A helminth parasitic infection diagnosed within 24 weeks prior to the date informed consent is obtained that has not been treated with, or has failed to respond to, standard of care therapy\n5. Asthma exacerbation requiring use of systemic corticosteroids, or an increase in maintenance dose of OCS, or acute upper/lower respiratory infections requiring antibiotics or antiviral medication within 30 days prior to Visit 2 (first benralizumab dose)\n6. A history of known immunodeficiency disorder including history of a positive human immunodeficiency virus (HIV) test\n7. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level \u22653 times the upper limit of normal (ULN) confirmed at Visit 1.\n8. Receipt of immunoglobulin or blood products within 30 days prior to the date informed consent is obtained\n9. Coincident primary adrenal failure (Addison's disease) or irreversible secondary hypoadrenalism due to another independent cause (e.g. pituitary tumour or its treatment)\n10. Co-existent inflammatory conditions for which chronic OCS doses are part of their maintenance treatment such as Giant Cell Arteritis, Polymyalgia Rheumatica\n11. Exclusion from genetic research may be for any of the exclusion criteria specified in the main study or allogeneic bone marrow transplant, Non-leukocyte depleted whole blood transfusion within 120 days of genetic sample collection\n12. Current night-shift workers", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "130 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Research Site", "city": "Flagstaff", "state": "Arizona", "zip": "86001", "country": "United States", "geoPoint": {"lat": 35.19807, "lon": -111.65127}}, {"facility": "Research Site", "city": "Los Angeles", "state": "California", "zip": "90025", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Research Site", "city": "Aurora", "state": "Colorado", "zip": "80045", "country": "United States", "geoPoint": {"lat": 39.72943, "lon": -104.83192}}, {"facility": "Research Site", "city": "Newark", "state": "Delaware", "zip": "19713", "country": "United States", "geoPoint": {"lat": 39.68372, "lon": -75.74966}}, {"facility": "Research Site", "city": "Tampa", "state": "Florida", "zip": "33607", "country": "United States", "geoPoint": {"lat": 27.94752, "lon": -82.45843}}, {"facility": "Research Site", "city": "Winter Park", "state": "Florida", "zip": "32789-4681", "country": "United States", "geoPoint": {"lat": 28.6, "lon": -81.33924}}, {"facility": "Research Site", "city": "Albany", "state": "Georgia", "zip": "31707", "country": "United States", "geoPoint": {"lat": 31.57851, "lon": -84.15574}}, {"facility": "Research Site", "city": "Atlanta", "state": "Georgia", "zip": "30322", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"facility": "Research Site", "city": "Savannah", "state": "Georgia", "zip": "31405", "country": "United States", "geoPoint": {"lat": 32.08354, "lon": -81.09983}}, {"facility": "Research Site", "city": "Normal", "state": "Illinois", "zip": "61761", "country": "United States", "geoPoint": {"lat": 40.5142, "lon": -88.99063}}, {"facility": "Research Site", "city": "Georgetown", "state": "Kentucky", "zip": "40324", "country": "United States", "geoPoint": {"lat": 38.2098, "lon": -84.55883}}, {"facility": "Research Site", "city": "Lakeside Park", "state": "Kentucky", "zip": "41017", "country": "United States", "geoPoint": {"lat": 39.03562, "lon": -84.56911}}, {"facility": "Research Site", "city": "Ann Arbor", "state": "Michigan", "zip": "48109", "country": "United States", "geoPoint": {"lat": 42.27756, "lon": -83.74088}}, {"facility": "Research Site", "city": "Minneapolis", "state": "Minnesota", "zip": "55402", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "Research Site", "city": "Saint Paul", "state": "Minnesota", "zip": "55101", "country": "United States", "geoPoint": {"lat": 44.94441, "lon": -93.09327}}, {"facility": "Research Site", "city": "Saint Louis", "state": "Missouri", "zip": "63156", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Research Site", "city": "New York", "state": "New York", "zip": "10016", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "Research Site", "city": "Chapel Hill", "state": "North Carolina", "zip": "27599", "country": "United States", "geoPoint": {"lat": 35.9132, "lon": -79.05584}}, {"facility": "Research Site", "city": "Greenville", "state": "North Carolina", "zip": "27834", "country": "United States", "geoPoint": {"lat": 35.61266, "lon": -77.36635}}, {"facility": "Research Site", "city": "Wilmington", "state": "North Carolina", "zip": "28401", "country": "United States", "geoPoint": {"lat": 34.22573, "lon": -77.94471}}, {"facility": "Research Site", "city": "Winston-Salem", "state": "North Carolina", "zip": "27104", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "Research Site", "city": "DuBois", "state": "Pennsylvania", "zip": "15801", "country": "United States", "geoPoint": {"lat": 41.11923, "lon": -78.76003}}, {"facility": "Research Site", "city": "North Charleston", "state": "South Carolina", "zip": "29406", "country": "United States", "geoPoint": {"lat": 32.85462, "lon": -79.97481}}, {"facility": "Research Site", "city": "Buenos Aires", "zip": "C1121ABE", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Research Site", "city": "Caba", "zip": "C1012AAR", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Research Site", "city": "Cap. Fed", "zip": "1280", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Research Site", "city": "Ciudad Aut\u00f3noma de Bs. As.", "zip": "1426", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Research Site", "city": "Ciudad Aut\u00f3noma de Buenos Aire", "zip": "C1440BRR", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Research Site", "city": "Florencio Varela", "zip": "1888", "country": "Argentina", "geoPoint": {"lat": -34.82722, "lon": -58.39556}}, {"facility": "Research Site", "city": "Mar del Plata", "zip": "7600", "country": "Argentina", "geoPoint": {"lat": -38.00228, "lon": -57.55754}}, {"facility": "Research Site", "city": "Mendoza", "zip": "M5500GIP", "country": "Argentina", "geoPoint": {"lat": -32.89084, "lon": -68.82717}}, {"facility": "Research Site", "city": "Monte Grande", "zip": "1842", "country": "Argentina"}, {"facility": "Research Site", "city": "Ranelagh", "zip": "1886", "country": "Argentina", "geoPoint": {"lat": -34.79591, "lon": -58.1977}}, {"facility": "Research Site", "city": "Rosario", "zip": "2000", "country": "Argentina", "geoPoint": {"lat": -32.94682, "lon": -60.63932}}, {"facility": "Research Site", "city": "Rosario", "zip": "S2000DEJ", "country": "Argentina", "geoPoint": {"lat": -32.94682, "lon": -60.63932}}, {"facility": "Research Site", "city": "Bruxelles", "zip": "1200", "country": "Belgium", "geoPoint": {"lat": 50.85045, "lon": 4.34878}}, {"facility": "Research Site", "city": "Erpent", "zip": "5101", "country": "Belgium", "geoPoint": {"lat": 50.45116, "lon": 4.90557}}, {"facility": "Research Site", "city": "Gent", "zip": "9000", "country": "Belgium", "geoPoint": {"lat": 51.05, "lon": 3.71667}}, {"facility": "Research Site", "city": "Botucatu", "zip": "18618-970", "country": "Brazil", "geoPoint": {"lat": -22.88583, "lon": -48.445}}, {"facility": "Research Site", "city": "Londrina", "zip": "86057-970", "country": "Brazil", "geoPoint": {"lat": -23.31028, "lon": -51.16278}}, {"facility": "Research Site", "city": "Maringa", "zip": "87015-000", "country": "Brazil", "geoPoint": {"lat": -23.42528, "lon": -51.93861}}, {"facility": "Research Site", "city": "Porto Alegre", "zip": "90610-000", "country": "Brazil", "geoPoint": {"lat": -30.03306, "lon": -51.23}}, {"facility": "Research Site", "city": "Porto Alegre", "zip": "91350-200", "country": "Brazil", "geoPoint": {"lat": -30.03306, "lon": -51.23}}, {"facility": "Research Site", "city": "Salvador", "zip": "40060-330", "country": "Brazil", "geoPoint": {"lat": -12.97111, "lon": -38.51083}}, {"facility": "Research Site", "city": "Santo Andre", "zip": "09060-650", "country": "Brazil", "geoPoint": {"lat": -23.66389, "lon": -46.53833}}, {"facility": "Research Site", "city": "Santo Andre", "zip": "09080-110", "country": "Brazil", "geoPoint": {"lat": -23.66389, "lon": -46.53833}}, {"facility": "Research Site", "city": "Sorocaba", "zip": "18040-425", "country": "Brazil", "geoPoint": {"lat": -23.50167, "lon": -47.45806}}, {"facility": "Research Site", "city": "Uberlandia", "zip": "38411-186", "country": "Brazil", "geoPoint": {"lat": -18.91861, "lon": -48.27722}}, {"facility": "Research Site", "city": "Vancouver", "state": "British Columbia", "zip": "V6Z 1Y6", "country": "Canada", "geoPoint": {"lat": 49.24966, "lon": -123.11934}}, {"facility": "Research Site", "city": "Vancouver", "state": "CA", "zip": "V5Z 4E1", "country": "Canada", "geoPoint": {"lat": 49.24966, "lon": -123.11934}}, {"facility": "Research Site", "city": "Ajax", "state": "Ontario", "zip": "L1S 2J5", "country": "Canada", "geoPoint": {"lat": 43.85012, "lon": -79.03288}}, {"facility": "Research Site", "city": "Mississauga", "state": "Ontario", "zip": "L5A 3V4", "country": "Canada", "geoPoint": {"lat": 43.5789, "lon": -79.6583}}, {"facility": "Research Site", "city": "Ottawa", "state": "Ontario", "zip": "K1H 1E4", "country": "Canada", "geoPoint": {"lat": 45.41117, "lon": -75.69812}}, {"facility": "Research Site", "city": "Toronto", "state": "Ontario", "zip": "M4V 1R2", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "Research Site", "city": "Quebec", "zip": "G1V 4W2", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "Research Site", "city": "Barranquilla", "zip": "080020", "country": "Colombia", "geoPoint": {"lat": 10.96854, "lon": -74.78132}}, {"facility": "Research Site", "city": "Bogota", "zip": "110221", "country": "Colombia", "geoPoint": {"lat": 4.60971, "lon": -74.08175}}, {"facility": "Research Site", "city": "Cali", "zip": "76001000", "country": "Colombia", "geoPoint": {"lat": 3.43722, "lon": -76.5225}}, {"facility": "Research Site", "city": "Cartagena", "zip": "130013", "country": "Colombia", "geoPoint": {"lat": 10.39972, "lon": -75.51444}}, {"facility": "Research Site", "city": "Floridablanca", "zip": "681004", "country": "Colombia", "geoPoint": {"lat": 7.06222, "lon": -73.08644}}, {"facility": "Research Site", "city": "Manizales", "zip": "17001", "country": "Colombia", "geoPoint": {"lat": 5.06889, "lon": -75.51738}}, {"facility": "Research Site", "city": "Medellin", "zip": "5001000", "country": "Colombia", "geoPoint": {"lat": 6.25184, "lon": -75.56359}}, {"facility": "Research Site", "city": "Herlev", "zip": "2730", "country": "Denmark", "geoPoint": {"lat": 55.72366, "lon": 12.43998}}, {"facility": "Research Site", "city": "Hvidovre", "zip": "2650", "country": "Denmark", "geoPoint": {"lat": 55.65719, "lon": 12.47364}}, {"facility": "Research Site", "city": "Vejle", "zip": "7100", "country": "Denmark", "geoPoint": {"lat": 55.70927, "lon": 9.5357}}, {"facility": "Research Site", "city": "\u00c5lborg", "zip": "9000", "country": "Denmark"}, {"facility": "Research Site", "city": "ANGERS Cedex 9", "zip": "49933", "country": "France", "geoPoint": {"lat": 47.46667, "lon": -0.55}}, {"facility": "Research Site", "city": "Besancon Cedex", "zip": "25030", "country": "France", "geoPoint": {"lat": 47.24878, "lon": 6.01815}}, {"facility": "Research Site", "city": "Colmar Cedex", "zip": "68024", "country": "France", "geoPoint": {"lat": 48.08333, "lon": 7.36667}}, {"facility": "Research Site", "city": "Marseille", "zip": "13300", "country": "France", "geoPoint": {"lat": 43.29551, "lon": 5.38958}}, {"facility": "Research Site", "city": "NICE Cedex 01", "zip": "06001", "country": "France", "geoPoint": {"lat": 43.70313, "lon": 7.26608}}, {"facility": "Research Site", "city": "Orl\u00e9ans", "zip": "45067", "country": "France", "geoPoint": {"lat": 47.90289, "lon": 1.90389}}, {"facility": "Research Site", "city": "Reims", "zip": "51092", "country": "France", "geoPoint": {"lat": 49.25, "lon": 4.03333}}, {"facility": "Research Site", "city": "Suresnes Cedex", "zip": "92151", "country": "France", "geoPoint": {"lat": 48.87143, "lon": 2.22929}}, {"facility": "Research Site", "city": "Tours", "zip": "37000", "country": "France", "geoPoint": {"lat": 47.38333, "lon": 0.68333}}, {"facility": "Research Site", "city": "Bamberg", "zip": "96049", "country": "Germany", "geoPoint": {"lat": 49.89873, "lon": 10.90067}}, {"facility": "Research Site", "city": "Berlin", "zip": "12203", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Research Site", "city": "Berlin", "zip": "13187", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Research Site", "city": "Darmstadt", "zip": "64283", "country": "Germany", "geoPoint": {"lat": 49.87167, "lon": 8.65027}}, {"facility": "Research Site", "city": "Frankfurt", "zip": "60596", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Research Site", "city": "Gro\u00dfhansdorf", "zip": "22927", "country": "Germany", "geoPoint": {"lat": 53.66667, "lon": 10.28333}}, {"facility": "Research Site", "city": "Heidelberg", "zip": "69126", "country": "Germany", "geoPoint": {"lat": 49.40768, "lon": 8.69079}}, {"facility": "Research Site", "city": "K\u00f6ln", "zip": "51069", "country": "Germany", "geoPoint": {"lat": 50.93333, "lon": 6.95}}, {"facility": "Research Site", "city": "Leipzig", "zip": "04207", "country": "Germany", "geoPoint": {"lat": 51.33962, "lon": 12.37129}}, {"facility": "Research Site", "city": "L\u00fcbeck", "zip": "23552", "country": "Germany", "geoPoint": {"lat": 53.86893, "lon": 10.68729}}, {"facility": "Research Site", "city": "Magdeburg", "zip": "39120", "country": "Germany", "geoPoint": {"lat": 52.12773, "lon": 11.62916}}, {"facility": "Research Site", "city": "M\u00fcnchen", "zip": "81675", "country": "Germany", "geoPoint": {"lat": 48.13743, "lon": 11.57549}}, {"facility": "Research Site", "city": "Firenze", "zip": "50134", "country": "Italy", "geoPoint": {"lat": 43.77925, "lon": 11.24626}}, {"facility": "Research Site", "city": "Milano", "zip": "20162", "country": "Italy", "geoPoint": {"lat": 45.46427, "lon": 9.18951}}, {"facility": "Research Site", "city": "Napoli", "zip": "80131", "country": "Italy", "geoPoint": {"lat": 40.85216, "lon": 14.26811}}, {"facility": "Research Site", "city": "Palermo", "zip": "90129", "country": "Italy", "geoPoint": {"lat": 38.13205, "lon": 13.33561}}, {"facility": "Research Site", "city": "Pisa", "zip": "56100", "country": "Italy", "geoPoint": {"lat": 43.70853, "lon": 10.4036}}, {"facility": "Research Site", "city": "Roma", "zip": "00185", "country": "Italy", "geoPoint": {"lat": 41.89193, "lon": 12.51133}}, {"facility": "Research Site", "city": "Sassari", "zip": "07100", "country": "Italy", "geoPoint": {"lat": 40.72586, "lon": 8.55552}}, {"facility": "Research Site", "city": "Tradate", "zip": "21049", "country": "Italy", "geoPoint": {"lat": 45.70843, "lon": 8.90763}}, {"facility": "Research Site", "city": "Del. Cuauhtemoc", "zip": "06700", "country": "Mexico"}, {"facility": "Research Site", "city": "Durango", "zip": "43080", "country": "Mexico", "geoPoint": {"lat": 24.02032, "lon": -104.65756}}, {"facility": "Research Site", "city": "Guadalajara", "zip": "44100", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Research Site", "city": "Guadalajara", "zip": "44130", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Research Site", "city": "M\u00e9rida", "zip": "97070", "country": "Mexico", "geoPoint": {"lat": 20.97537, "lon": -89.61696}}, {"facility": "Research Site", "city": "Veracruz", "zip": "91910", "country": "Mexico", "geoPoint": {"lat": 19.18095, "lon": -96.1429}}, {"facility": "Research Site", "city": "Villahermosa", "zip": "86035", "country": "Mexico", "geoPoint": {"lat": 17.98689, "lon": -92.93028}}, {"facility": "Research Site", "city": "Bia\u0142ystok", "zip": "15-044", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "Research Site", "city": "Bia\u0142ystok", "zip": "15-430", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "Research Site", "city": "Gda\u0144sk", "zip": "80-214", "country": "Poland", "geoPoint": {"lat": 54.35205, "lon": 18.64637}}, {"facility": "Research Site", "city": "Krak\u00f3w", "zip": "31-011", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Research Site", "city": "Lubin", "zip": "59-300", "country": "Poland", "geoPoint": {"lat": 51.40089, "lon": 16.20149}}, {"facility": "Research Site", "city": "Ostrowiec \u015awi\u0119tokrzyski", "zip": "27-400", "country": "Poland", "geoPoint": {"lat": 50.92936, "lon": 21.38525}}, {"facility": "Research Site", "city": "Pozna\u0144", "zip": "60-693", "country": "Poland", "geoPoint": {"lat": 52.40692, "lon": 16.92993}}, {"facility": "Research Site", "city": "Pozna\u0144", "zip": "60-823", "country": "Poland", "geoPoint": {"lat": 52.40692, "lon": 16.92993}}, {"facility": "Research Site", "city": "Rzesz\u00f3w", "zip": "35-051", "country": "Poland", "geoPoint": {"lat": 50.04132, "lon": 21.99901}}, {"facility": "Research Site", "city": "Sosnowiec", "zip": "41-200", "country": "Poland", "geoPoint": {"lat": 50.28682, "lon": 19.10385}}, {"facility": "Research Site", "city": "Tarn\u00f3w", "zip": "33-100", "country": "Poland", "geoPoint": {"lat": 50.01381, "lon": 20.98698}}, {"facility": "Research Site", "city": "Wielu\u0144", "zip": "98-300", "country": "Poland", "geoPoint": {"lat": 51.22097, "lon": 18.56964}}, {"facility": "Research Site", "city": "Wroc\u0142aw", "zip": "50-449", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "Research Site", "city": "Izhevsk", "zip": "426061", "country": "Russian Federation", "geoPoint": {"lat": 56.84976, "lon": 53.20448}}, {"facility": "Research Site", "city": "Kirov", "zip": "610014", "country": "Russian Federation", "geoPoint": {"lat": 58.59665, "lon": 49.66007}}, {"facility": "Research Site", "city": "Moscow", "zip": "115478", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Research Site", "city": "Omsk", "zip": "644043", "country": "Russian Federation", "geoPoint": {"lat": 54.99244, "lon": 73.36859}}, {"facility": "Research Site", "city": "Omsk", "zip": "644112", "country": "Russian Federation", "geoPoint": {"lat": 54.99244, "lon": 73.36859}}, {"facility": "Research Site", "city": "Saint Petersburg", "zip": "194354", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Research Site", "city": "Saint Petersburg", "zip": "195257", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Research Site", "city": "Ulyanovsk", "zip": "432009", "country": "Russian Federation", "geoPoint": {"lat": 54.32824, "lon": 48.38657}}, {"facility": "Research Site", "city": "C\u00e1diz", "zip": "11009", "country": "Spain", "geoPoint": {"lat": 36.52672, "lon": -6.2891}}, {"facility": "Research Site", "city": "Marbella (M\u00e1laga)", "zip": "29603", "country": "Spain"}, {"facility": "Research Site", "city": "M\u00e9rida", "zip": "06800", "country": "Spain", "geoPoint": {"lat": 38.91611, "lon": -6.34366}}, {"facility": "Research Site", "city": "Ourense", "zip": "32005", "country": "Spain", "geoPoint": {"lat": 42.33669, "lon": -7.86407}}, {"facility": "Research Site", "city": "Sant Joan Desp\u00ed (Barcelona)", "zip": "08970", "country": "Spain"}, {"facility": "Research Site", "city": "Santiago De Compostela-Coru\u00f1a", "zip": "15706", "country": "Spain"}, {"facility": "Research Site", "city": "Zaragoza", "zip": "50009", "country": "Spain", "geoPoint": {"lat": 41.65606, "lon": -0.87734}}, {"facility": "Research Site", "city": "Lund", "zip": "221 85", "country": "Sweden", "geoPoint": {"lat": 55.70584, "lon": 13.19321}}, {"facility": "Research Site", "city": "Kaohsiung Hsien", "zip": "83301", "country": "Taiwan"}, {"facility": "Research Site", "city": "Kaohsiung", "zip": "80756", "country": "Taiwan", "geoPoint": {"lat": 22.61626, "lon": 120.31333}}, {"facility": "Research Site", "city": "Taichung", "zip": "40447", "country": "Taiwan", "geoPoint": {"lat": 24.1469, "lon": 120.6839}}, {"facility": "Research Site", "city": "Taichung", "zip": "40705", "country": "Taiwan", "geoPoint": {"lat": 24.1469, "lon": 120.6839}}, {"facility": "Research Site", "city": "Taipei City", "zip": "110", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}, {"facility": "Research Site", "city": "Taipei", "zip": "10449", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}, {"facility": "Research Site", "city": "Taipei", "zip": "235", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}, {"facility": "Research Site", "city": "Yunlin", "zip": "640", "country": "Taiwan"}, {"facility": "Research Site", "city": "Bradford", "zip": "BND9 6RJ", "country": "United Kingdom", "geoPoint": {"lat": 53.79391, "lon": -1.75206}}, {"facility": "Research Site", "city": "Cambridge", "zip": "CB2 0QQ", "country": "United Kingdom", "geoPoint": {"lat": 52.2, "lon": 0.11667}}, {"facility": "Research Site", "city": "London", "zip": "SE1 9RT", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}, {"facility": "Research Site", "city": "London", "zip": "SW3 6HP", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}, {"facility": "Research Site", "city": "Nottingham", "zip": "NG5 1PB", "country": "United Kingdom", "geoPoint": {"lat": 52.9536, "lon": -1.15047}}]}, "referencesModule": {"references": [{"pmid": "34619104", "type": "DERIVED", "citation": "Menzies-Gow A, Gurnell M, Heaney LG, Corren J, Bel EH, Maspero J, Harrison T, Jackson DJ, Price D, Lugogo N, Kreindler J, Burden A, de Giorgio-Miller A, Padilla K, Martin UJ, Garcia Gil E. Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. Lancet Respir Med. 2022 Jan;10(1):47-58. doi: 10.1016/S2213-2600(21)00352-0. Epub 2021 Oct 4. Erratum In: Lancet Respir Med. 2021 Dec;9(12):e114."}, {"pmid": "31579676", "type": "DERIVED", "citation": "Menzies-Gow A, Corren J, Bel EH, Maspero J, Heaney LG, Gurnell M, Wessman P, Martin UJ, Siddiqui S, Garcia Gil E. Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial. ERJ Open Res. 2019 Sep 25;5(3):00009-2019. doi: 10.1183/23120541.00009-2019. eCollection 2019 Jul."}], "seeAlsoLinks": [{"label": "CSP", "url": "https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D3250C00065&amp;attachmentIdentifier=ecf72bab-8195-4bbb-8146-15bdb632a43a&amp;fileName=d3250c00065-csp-v4_Redacted.pdf&amp;versionIdentifier="}, {"label": "Statistical Analysis Plan (SAP)", "url": "https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D3250C00065&amp;attachmentIdentifier=c9237f6c-c83b-4019-8b75-9ed31b8fd5d0&amp;fileName=d3250c00065-sap-ed-4-Redacted.pdf&amp;versionIdentifier="}, {"label": "CSR Synopsis", "url": "https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D3250C00065&amp;attachmentIdentifier=bf47c3cc-9aeb-4c0a-9026-61831356ca8c&amp;fileName=d3250c00065-study-synopsis_Redacted.pdf&amp;versionIdentifier="}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.", "infoTypes": ["STUDY_PROTOCOL", "SAP"], "timeFrame": "AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.", "accessCriteria": "When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.", "url": "https://astrazenecagroup-dt.pharmacm.com/DT/Home"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "In PONENTE, at the first visit, ie, the enrollment visit 1, patients were assigned an enrollment number and then evaluated regarding the protocol mandated inclusion and exclusion criteria. After screening and evaluation, only those eligible to receive Benralizumab 30 mg were assigned treatment and entered a 4 week induction phase on a stable dose of oral corticosteroids (OCS). In Substudy, patients were treated according to healthcare provider discretion with no IP provided by sponsor.", "recruitmentDetails": "705 participants provided informed consent and were assigned a unique enrollment number prior to screening. Of the 705 patients screened, 598 (84.8%) were eligible to receive Benralizumab 30 mg and entered the study. All 598 (100%) patients received the study drug. 195 of the 538 patients who completed the main study treatment enrolled into PONENTE Long Term Follow Up Substudy.", "groups": [{"id": "FG000", "title": "Benra 30 mg", "description": "For main study (period 1 (OCS reduction period) and period 2 (maintenance period)): Benralizumab 30 mg administered subcutaneously every 4 weeks. For substudy (period 3 (long term follow up substudy), asthma treatment as per healthcare provider discretion, including Benralizumab 30 mg administered subcutaneously every 4-8 weeks or other biologics."}], "periods": [{"title": "Period 1: To End of OCS Reduction Phase", "milestones": [{"type": "STARTED", "comment": "Received study drug", "achievements": [{"groupId": "FG000", "numSubjects": "598"}]}, {"type": "COMPLETED", "comment": "Could not reduce OCS dose further according to protocol.", "achievements": [{"groupId": "FG000", "numSubjects": "563"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "35"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "10"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "7"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "6"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "5"}]}, {"type": "other", "reasons": [{"groupId": "FG000", "numSubjects": "3"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}, {"type": "Failure to meet inclusion/exclusion criteria", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}]}, {"title": "Period 2: Maintenance Phase", "milestones": [{"type": "STARTED", "comment": "Completed OCS reduction phase.", "achievements": [{"groupId": "FG000", "numSubjects": "563"}]}, {"type": "COMPLETED", "comment": "Marked 'Completed' to subject's status on the Disposition CRF", "achievements": [{"groupId": "FG000", "numSubjects": "536"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "27"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "4"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "3"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}, {"type": "Pregnancy", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "11"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}, {"type": "other", "reasons": [{"groupId": "FG000", "numSubjects": "3"}]}]}, {"title": "Period 3: Long Term Follow up Substudy", "milestones": [{"type": "STARTED", "comment": "Patients enrolled in long term follow up substudy", "achievements": [{"groupId": "FG000", "numSubjects": "195"}]}, {"type": "Asthma Treatment as Per Healthcare Provider Discretion", "comment": "Treated as per healthcare provider's discretion, including Benra 30 mg administered subcutaneously every 4-8 weeks or other biologics. IP or medications were not provided by the sponsor.", "achievements": [{"groupId": "FG000", "numSubjects": "195"}]}, {"type": ">=50% Any Biologic", "comment": "\\>=50% exposure to any biologic treatment for asthma from the end of maintenance phase of the main study to the Long Term Follow Up visit", "achievements": [{"groupId": "FG000", "numSubjects": "78"}]}, {"type": ">=50% Benra", "comment": "\\>=50% exposure to benralizumab from the end of maintenance phase of the main study to the Long Term follow Up visit, and no previous or concurrent exposure to any other biologic during this period", "achievements": [{"groupId": "FG000", "numSubjects": "69"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "195"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Full analysis set", "groups": [{"id": "BG000", "title": "Benra 30 mg", "description": "For main study (period 1 (OCS reduction period) and period 2 (maintenance period)): Benralizumab 30 mg administered subcutaneously every 4 weeks. For substudy (period 3 (long term follow up substudy), asthma treatment as per healthcare provider discretion, including Benralizumab 30 mg administered subcutaneously every 4-8 weeks or other biologics."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "598"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "598"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "53.3", "spread": "13.59"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "598"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "383"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "215"}]}]}]}, {"title": "Race/Ethnicity, Customized", "populationDescription": "Race of 9 patients in Full Analysis Set is not recorded.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "589"}]}], "categories": [{"title": "White", "measurements": [{"groupId": "BG000", "value": "475"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "26"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "29"}]}, {"title": "Native Hawaiian or other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "1"}]}, {"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "46"}]}, {"title": "Other", "measurements": [{"groupId": "BG000", "value": "12"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Patients Who Achieve 100% Reduction in Daily OCS Dose", "description": "Patients who achieve 100% reduction in daily OCS dose that are sustained over at least 4 weeks without worsening of asthma", "populationDescription": "Full analysis set - All enrolled patients who received at least one dose of benralizumab are included in the FAS, irrespective of their protocol adherence and continued participation in the study.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Baseline to end of OCS reduction phase, an average of approximately 200 days (The duration of the OCS reduction phase may vary based on asthma exacerbations, asthma worsening, HPA integrity , or other safety issues altering the OCS titration schedule.)", "groups": [{"id": "OG000", "title": "Benra 30 mg", "description": "For main study (period 1 (OCS reduction period) and period 2 (maintenance period)): Benralizumab 30 mg administered subcutaneously every 4 weeks. For substudy (period 3 (long term follow up substudy), asthma treatment as per healthcare provider discretion, including Benralizumab 30 mg administered subcutaneously every 4-8 weeks or other biologics."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "598"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "376"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "statisticalMethod": "Clopper-Pearson Exact CI", "statisticalComment": "One sample Confidence Interval", "paramType": "percentage", "paramValue": "62.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "58.86", "ciUpperLimit": "66.76", "estimateComment": "Percentage of patients who achieved 100% reduction in daily OCS dose that are sustained over at least 4 weeks without worsening of asthma"}]}, {"type": "PRIMARY", "title": "Patients Who Achieve 100% Reduction or a Daily OCS Dose of <=5mg", "description": "Patients who achieve 100% reduction or a daily OCS dose of \\<=5mg, if reason for no further OCS reduction is Adrenal Insufficiency, that are sustained over at least 4 weeks without worsening of asthma", "populationDescription": "All enrolled patients who received at least one dose of benralizumab are included in the FAS, irrespective of their protocol adherence and continued participation in the study.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Baseline to end of OCS reduction phase, an average of approximately 200 days (The duration of the OCS reduction phase may vary based on asthma exacerbations, asthma worsening, HPA integrity , or other safety issues altering the OCS titration schedule.)", "groups": [{"id": "OG000", "title": "Benra 30 mg", "description": "For main study (period 1 (OCS reduction period) and period 2 (maintenance period)): Benralizumab 30 mg administered subcutaneously every 4 weeks. For substudy (period 3 (long term follow up substudy), asthma treatment as per healthcare provider discretion, including Benralizumab 30 mg administered subcutaneously every 4-8 weeks or other biologics."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "598"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "490"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "statisticalMethod": "Clopper-Pearson Exact CI", "statisticalComment": "One sample Confidence Interval", "paramType": "percentage", "paramValue": "81.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "78.62", "ciUpperLimit": "84.94", "estimateComment": "Percentage of patients who achieve 100% reduction or a daily OCS dose of \\<=5mg, if reason for no further OCS reduction is Adrenal Insufficiency, that are sustained over at least 4 weeks without worsening of asthma"}]}, {"type": "SECONDARY", "title": "Patients Who Achieve a Daily OCS of \u22645mg", "description": "Patients who achieve a daily OCS dose of \u22645 mg (regardless of reason for no further OCS reduction), that are sustained over at least 4 weeks without worsening of asthma", "populationDescription": "Full analysis set - All enrolled patients who received at least one dose of benralizumab are included in the FAS, irrespective of their protocol adherence and continued participation in the study.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Baseline to end of OCS reduction phase, an average of approximately 200 days (The duration of the OCS reduction phase may vary based on asthma exacerbations, asthma worsening, HPA integrity , or other safety issues altering the OCS titration schedule.)", "groups": [{"id": "OG000", "title": "Benra 30 mg", "description": "For main study (period 1 (OCS reduction period) and period 2 (maintenance period)): Benralizumab 30 mg administered subcutaneously every 4 weeks. For substudy (period 3 (long term follow up substudy), asthma treatment as per healthcare provider discretion, including Benralizumab 30 mg administered subcutaneously every 4-8 weeks or other biologics."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "598"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "547"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "statisticalMethod": "Clopper-Pearson Exact CI", "statisticalComment": "One sample Confidence Interval", "paramType": "percentage", "paramValue": "91.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "88.94", "ciUpperLimit": "93.58", "estimateComment": "Percentage of patients who achieve a daily OCS dose of \u22645 mg (regardless of reason for no further OCS reduction), that are sustained over at least 4 weeks without worsening of asthma"}]}, {"type": "SECONDARY", "title": "Patients Who Achieve a \u226590%, \u226575%, and \u226550% Reduction in Daily OCS Dose", "description": "Patients who achieve a \u226590%, \u226575%, and \u226550% reduction in daily OCS dose that are sustained over at least 4 weeks without worsening of asthma", "populationDescription": "Full analysis set - All enrolled patients who received at least one dose of benralizumab are included in the FAS, irrespective of their protocol adherence and continued participation in the study.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Baseline to end of OCS reduction phase, an average of approximately 200 days (The duration of the OCS reduction phase may vary based on asthma exacerbations, asthma worsening, HPA integrity , or other safety issues altering the OCS titration schedule.)", "groups": [{"id": "OG000", "title": "Benra 30 mg", "description": "For main study (period 1 (OCS reduction period) and period 2 (maintenance period)): Benralizumab 30 mg administered subcutaneously every 4 weeks. For substudy (period 3 (long term follow up substudy), asthma treatment as per healthcare provider discretion, including Benralizumab 30 mg administered subcutaneously every 4-8 weeks or other biologics."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "598"}]}], "classes": [{"title": "\u226590% reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "383"}]}]}, {"title": "\u226575% reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "412"}]}]}, {"title": "\u226550% reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "489"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "statisticalMethod": "Clopper-Pearson Exact CI", "statisticalComment": "One sample Confidence Interval (\u226590% reduction)", "paramType": "percentage", "paramValue": "64.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "60.06", "ciUpperLimit": "67.90", "estimateComment": "Percentage of patients who achieve \\>=90% reduction in daily OCS dose that are sustained over at least 4 weeks without worsening of asthma"}, {"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "statisticalMethod": "Clopper-Pearson Exact CI", "statisticalComment": "One sample Confidence Interval (\\>=75% reduction)", "paramType": "percentage", "paramValue": "68.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "65.02", "ciUpperLimit": "72.59", "estimateComment": "Percentage of patients who achieve \\>=75% reduction in daily OCS dose that are sustained over at least 4 weeks without worsening of asthma"}, {"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "statisticalMethod": "Clopper-Pearson Exact CI", "statisticalComment": "One sample Confidence Interval (\\>=50% reduction)", "paramType": "percentage", "paramValue": "81.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "78.44", "ciUpperLimit": "84.79", "estimateComment": "Percentage of patients who achieve \\>=50% reduction in daily OCS dose that are sustained over at least 4 weeks without worsening of asthma"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Average Daily OCS Dose (mg)", "description": "Change from baseline in average daily OCS dose (mg) from start of OCS reduction to end of the OCS reduction phase", "populationDescription": "Full analysis set - All enrolled patients who received at least one dose of benralizumab are included in the FAS, irrespective of their protocol adherence and continued participation in the study.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg", "timeFrame": "Baseline to end of OCS reduction phase, an average of approximately 200 days (The duration of the OCS reduction phase may vary based on asthma exacerbations, asthma worsening, HPA integrity , or other safety issues altering the OCS titration schedule.)", "groups": [{"id": "OG000", "title": "Benra 30 mg", "description": "For main study (period 1 (OCS reduction period) and period 2 (maintenance period)): Benralizumab 30 mg administered subcutaneously every 4 weeks. For substudy (period 3 (long term follow up substudy), asthma treatment as per healthcare provider discretion, including Benralizumab 30 mg administered subcutaneously every 4-8 weeks or other biologics."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "593"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-8.50", "lowerLimit": "-9.10", "upperLimit": "-7.90"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "statisticalMethod": "Clopper-Pearson Exact CI", "statisticalComment": "One sample Confidence Interval", "paramType": "percentage change from baseline", "paramValue": "-76.92", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-79.90", "ciUpperLimit": "-73.94", "estimateComment": "Percentage change from baseline in daily OCS dose at the end of OCS reduction phase"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Patients Who Achieve 100% Reduction in Daily OCS Dose From Main Study Baseline OCS Dose to the End of the Long Term Follow up Substudy", "description": "Patients who achieve 100% reduction in daily OCS dose that are sustained over at least 4 weeks without worsening of asthma", "populationDescription": "Long term follow up analysis set - All patients who enrolled in Long Term Follow Up substudy", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "from main study baseline to the end of the long term follow up substudy, an average of approximate 922 days.", "groups": [{"id": "OG000", "title": "Asthma Treatment as Per Healthcare Provider Discretion", "description": "Treated as per healthcare provider's discretion, including Benra 30 mg administered every 4 to 8 weeks or other biologics. IP or medications were not provided by the sponsor."}, {"id": "OG001", "title": ">=50% Any Biologic", "description": "\\>=50% exposure to any biologic treatment for asthma from the end of maintenance phase of the main study to the Long Term Follow Up visit"}, {"id": "OG002", "title": ">=50% Benra", "description": "\\>=50% exposure to benralizumab from the end of maintenance phase of the main study to the Long Term follow Up visit, and no previous or concurrent exposure to any other biologic during this period"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "195"}, {"groupId": "OG001", "value": "78"}, {"groupId": "OG002", "value": "69"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "138"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "54"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Patients Who Achieve a Daily OCS Dose of \u22645 mg at the End of the Long Term Follow up Substudy", "description": "Patients who achieve a daily OCS dose of \u22645 mg (regardless of reason for no further OCS reduction), that are sustained over at least 4 weeks without worsening of asthma", "populationDescription": "Long Term Follow Up analysis set - All patients who enrolled in Long Term Follow Up substudy", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "from main study baseline to the end of the long term follow up substudy, an average of approximate 922 days.", "groups": [{"id": "OG000", "title": "Asthma Treatment as Per Healthcare Provider Discretion", "description": "Treated as per healthcare provider's discretion, including Benra 30 mg administered every 4 to 8 weeks or other biologics. IP or medications were not provided by the sponsor."}, {"id": "OG001", "title": ">=50% Any Biologic", "description": "\\>=50% exposure to any biologic treatment for asthma from the end of maintenance phase of the main study to the Long Term Follow Up visit"}, {"id": "OG002", "title": ">=50% Benra", "description": "\\>=50% exposure to benralizumab from the end of maintenance phase of the main study to the Long Term follow Up visit, and no previous or concurrent exposure to any other biologic during this period"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "195"}, {"groupId": "OG001", "value": "78"}, {"groupId": "OG002", "value": "69"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "177"}, {"groupId": "OG001", "value": "72"}, {"groupId": "OG002", "value": "65"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Patients Who Achieve \u226590%, \u226575%, \u226550% or >0% OCS Reduction From Main Study Baseline OCS Dose to the End of the Long Term Follow up Substudy", "description": "Patients who achieve a \u226590%, \u226575%, and \u226550% reduction in daily OCS dose that are sustained over at least 4 weeks without worsening of asthma", "populationDescription": "Long Term Follow Up analysis set - All patients who enrolled in Long Term Follow Up substudy", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "from main study baseline to the end of the long term follow up substudy, an average of approximate 922 days.", "groups": [{"id": "OG000", "title": "Asthma Treatment as Per Healthcare Provider Discretion", "description": "Treated as per healthcare provider's discretion, including Benra 30 mg administered every 4 to 8 weeks or other biologics. IP or medications were not provided by the sponsor."}, {"id": "OG001", "title": ">=50% Any Biologic", "description": "\\>=50% exposure to any biologic treatment for asthma from the end of maintenance phase of the main study to the Long Term Follow Up visit"}, {"id": "OG002", "title": ">=50% Benra", "description": "\\>=50% exposure to benralizumab from the end of maintenance phase of the main study to the Long Term follow Up visit, and no previous or concurrent exposure to any other biologic during this period"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "195"}, {"groupId": "OG001", "value": "78"}, {"groupId": "OG002", "value": "69"}]}], "classes": [{"title": ">=90% reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "141"}, {"groupId": "OG001", "value": "61"}, {"groupId": "OG002", "value": "55"}]}]}, {"title": ">=75% reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "64"}, {"groupId": "OG002", "value": "58"}]}]}, {"title": ">=50% reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "172"}, {"groupId": "OG001", "value": "71"}, {"groupId": "OG002", "value": "64"}]}]}, {"title": ">0% reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "175"}, {"groupId": "OG001", "value": "72"}, {"groupId": "OG002", "value": "65"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change in Daily OCS Dose (mg) From Main Study Baseline to the End of the Long Term Follow up Substudy", "description": "Change in average daily OCS dose (mg) from main study baseline to the end of the long term follow up substudy", "populationDescription": "Long Term Follow Up analysis set - All patients who enrolled in Long Term Follow Up substudy", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg", "timeFrame": "from main study baseline to the end of the long term follow up substudy, an average of approximate 922 days.", "groups": [{"id": "OG000", "title": "Asthma Treatment as Per Healthcare Provider Discretion", "description": "Treated as per healthcare provider's discretion, including Benra 30 mg administered every 4 to 8 weeks or other biologics. IP or medications were not provided by the sponsor."}, {"id": "OG001", "title": ">=50% Any Biologic", "description": "\\>=50% exposure to any biologic treatment for asthma from the end of maintenance phase of the main study to the Long Term Follow Up visit"}, {"id": "OG002", "title": ">=50% Benra", "description": "\\>=50% exposure to benralizumab from the end of maintenance phase of the main study to the Long Term follow Up visit, and no previous or concurrent exposure to any other biologic during this period"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "195"}, {"groupId": "OG001", "value": "78"}, {"groupId": "OG002", "value": "69"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-10.01", "lowerLimit": "-11.26", "upperLimit": "-8.76"}, {"groupId": "OG001", "value": "-10.28", "lowerLimit": "-12.16", "upperLimit": "-8.41"}, {"groupId": "OG002", "value": "-10.8", "lowerLimit": "-12.85", "upperLimit": "-8.75"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "timeFrame": "Main study: From first dose of study drug until end of study, with an average of 405 days. Substudy: on-study period, between the date of informed consent for the substudy and the last available visit or contact for a patient, with an average of 18 days.", "eventGroups": [{"id": "EG000", "title": "Benra 30 mg", "description": "For main study (period 1 (OCS reduction period) and period 2 (maintenance period)): Benralizumab 30 mg administered subcutaneously every 4 weeks.", "deathsNumAffected": 5, "deathsNumAtRisk": 598, "seriousNumAffected": 89, "seriousNumAtRisk": 598, "otherNumAffected": 181, "otherNumAtRisk": 598}, {"id": "EG001", "title": "Asthma Treatment as Per Healthcare Provider Discretion", "description": "Treated as per healthcare provider's discretion, including Benra 30 mg administered every 4 to 8 weeks or other biologics. IP or medications were not provided by the sponsor.", "deathsNumAffected": 0, "deathsNumAtRisk": 195, "seriousNumAffected": 0, "seriousNumAtRisk": 195, "otherNumAffected": 0, "otherNumAtRisk": 195}, {"id": "EG002", "title": ">=50% Any Biologic", "description": "\\>=50% exposure to any biologic treatment for asthma from the end of maintenance phase of the main study to the Long Term Follow Up visit", "deathsNumAffected": 0, "deathsNumAtRisk": 78, "seriousNumAffected": 0, "seriousNumAtRisk": 78, "otherNumAffected": 0, "otherNumAtRisk": 78}, {"id": "EG003", "title": ">=50% Benra", "description": "\\>=50% exposure to benralizumab from the end of maintenance phase of the main study to the Long Term follow Up visit, and no previous or concurrent exposure to any other biologic during this period", "deathsNumAffected": 0, "deathsNumAtRisk": 69, "seriousNumAffected": 0, "seriousNumAtRisk": 69, "otherNumAffected": 0, "otherNumAtRisk": 69}], "seriousEvents": [{"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Angina unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Cardiac arrest", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Myocardial ischaemia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Ventricular extrasystoles", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Meniere's disease", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Anal fistula", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Ileus", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Pancreatitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Pancreatitis acute", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Sudden cardiac death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "COVID-19", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Chronic sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Diverticulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "H1N1 influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Haemophilus infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Infected bite", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Lower respiratory tract infection bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Pelvic abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Peritonitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 11, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Pneumonia bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Pneumonia haemophilus", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Pneumonia influenzal", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Pneumonia pseudomonal", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Respiratory tract infection bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Urosepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Alcohol poisoning", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Craniocerebral injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Humerus fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Multiple fractures", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Post procedural haemorrhage", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Rib fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Spinal fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Tendon rupture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Oxygen saturation decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Diabetes mellitus inadequate control", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Type 2 diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Intervertebral disc protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Osteonecrosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Polymyalgia rheumatica", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Adenocarcinoma of colon", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Basal cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Malignant glioma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Neurofibroma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Uterine leiomyoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Apallic syndrome", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Carotid artery aneurysm", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Dizziness postural", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Generalised tonic-clonic seizure", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Sciatica", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Acute kidney injury", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Breast calcifications", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Acute respiratory failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Aspirin-exacerbated respiratory disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 33, "numAffected": 23, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Atelectasis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Chronic rhinosinusitis with nasal polyps", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Haemoptysis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Pharyngeal swelling", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Respiratory failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Embolism arterial", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Hypertensive emergency", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}], "otherEvents": [{"term": "Influenza like illness", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 34, "numAffected": 33, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 92, "numAffected": 64, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 22, "numAffected": 19, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 28, "numAffected": 25, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 31, "numAffected": 28, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 38, "numAffected": 29, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 21, "numAffected": 21, "numAtRisk": 598}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "During COVID-19 pandemic, for ongoing patients, patient dosing, and scheduled visits are inevitably impacted, but the primary endpoint was not impacted."}, "certainAgreement": {"piSponsorEmployee": true, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "\u2265 60 days prior to submission of material for publication/presentation, Institution and PI shall jointly provide AZ with material for review. No publication/presentation may include any of AZ's Confidential Information without AZ's written approval. AZ can request Inst. and PI to withhold material from submission for publication/presentation for an additional 90 days to allow AZ to establish and preserve its proprietary rights in the material being submitted for publication or presentation."}, "pointOfContact": {"title": "Maria Jison, MD Global Clinical Head, FASENRA, Late-stage R&I", "organization": "AstraZeneca", "email": "Maria.Jison@astrazeneca.com", "phone": "+13013980340"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2020-10-17", "uploadDate": "2023-05-09T03:55", "filename": "Prot_008.pdf", "size": 3726780}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2022-11-07", "uploadDate": "2023-03-02T04:44", "filename": "SAP_009.pdf", "size": 4184944}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2022-03-04", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M14511", "name": "Pulmonary Eosinophilia", "relevance": "LOW"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "BC15", "name": "Blood and Lymph Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000571386", "term": "Benralizumab"}], "ancestors": [{"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}], "browseLeaves": [{"id": "M287399", "name": "Benralizumab", "asFound": "Aorta", "relevance": "HIGH"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}